JWJorge Alfredo Wong

Jorge Alfredo Wong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jorge Alfredo Wong has a total of 218 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Rationale, design, and experiences from the vanguard phase of the bariatric surgery for the reduction of cardiovascular events (BRAVE) trial

    by Jorge A. Wong, David Conen, Aristithes Doumouras, Emma Van Reekum, Shrikant I. Bangdiwala, Kumar Balasubramanian, Shaheena Bashir, Sumathy Rangarajan, Marie-Eve Piché, Myriam Pettigrew, et al.

  • Open Access

    Prevalence and Clinical Outcomes of Subclinical Atrial Fibrillation After Heart Failure Hospitalization

    by Jorge A. Wong, Priya Mistry, Ameen Patel, Umjeet Jolly, Alex Benz, Fei Yuan, Natalia Pinilla-Echeverri, Ghaith Almidani, Nicole Latendresse, Alex Grinvalds, et al.

  • Open Access

    Intracardiac echocardiography–derived cavotricuspid isthmus morphology score for estimating procedural complexity in typical atrial flutter

    by Mustafa Gabarin, Majid Abonab, Juan Gabriel Acosta, Ziad Arow, Abdulrahman Alfraih, Guy Amit, Javier Bonacina, Mazin Alrasheed, Jason Roberts, Nigel Tan, et al.

    Graphical Abstract ICE-derived CTI morphology score and procedural outcomes. (A) Representative ICE images illustrating key CTI anatomical features used to derive the CTI morphology score, including flat vs. concave CTI, pouch formation, ridge, and prominent Eustachian ridge/valve. The scoring system (range 0–6) assigns points for CTI length > 35 mm (1), pouch (1), ridge (1), thick/prominent Eustachian ridge or valve (2), and concave CTI shape (1). Patients were categorized as mild (0–1), moderate (2–3), or severe (4–6) anatomical complexity. (B) Association between CTI morphology score and total RFA time. Each 1-point increase in CTI score was associated with a significant increase in ablation time (β ≈ 50 s per point; P < 0.001). (C) Association between CTI morphology score and number of radiofrequency applications delivered. Higher anatomical complexity correlated with increased lesion burden (≈3–4 additional applications per score point; P < 0.001). (D) Receiver operating characteristic curve evaluating the ability of the CTI morphology score to predict late AFL recurrence (>3 months), demonstrating modest discriminative performance (AUC ≈ 0.60). AFL, atrial flutter; CTI, cavotricuspid isthmus; ICE, intracardiac echocardiography; RFA, radiofrequency ablation; ROC, receiver operating characteristic. For image description, please refer to the figure legend and surrounding text.

  • Open Access

    Monitoring time-to-detection of recurrent atrial fibrillation in patients with transient new-onset atrial fibrillation detected initially during hospitalization for noncardiac surgery or medical illness

    by William F. McIntyre, Linda S. Johnson, Alexander P. Benz, Maria E. Vadakken, Nicole R. Latendresse, Chinthanie Ramasundarahettige, Faith Kirabo, Jorge A. Wong, Jason D. Roberts, Jeff S. Healey


  • Impact of Metabolic Surgery on Cardiovascular Disease Outcomes

    by Marie-Eve Piché, Paul Poirier, Jorge A. Wong

  • Top Cited Papers

    Atrial Fibrillation Ablation in Heart Failure With Reduced vs Preserved Ejection Fraction

    by Alireza Oraii, William F. McIntyre, Ratika Parkash, Krzysztof Kowalik, Ghazal Razeghi, Alexander P. Benz, Emilie P. Belley-Côté, David Conen, Stuart J. Connolly, Anthony S. L. Tang, et al.

    Importance: Catheter ablation is associated with reduced heart failure (HF) hospitalization and death in select patients with atrial fibrillation (AF) and heart failure with reduced ejection fraction (HFrEF). However, the benefit in patients with HF with preserved ejection fraction (HFpEF) is uncertain.Objective: To investigate whether catheter ablation for AF is associated with reduced HF-related outcomes according to HF phenotype.Data Source: A systematic search of MEDLINE, Embase, and Cochrane Central was conducted among studies published from inception to September 2023.Study Selection: Parallel-group randomized clinical trials (RCTs) comparing catheter ablation with conventional rate or rhythm control therapies in patients with HF, New York Heart Association functional class II or greater, and a history of paroxysmal or persistent AF were included. Pairs of independent reviewers screened 7531 titles and abstracts, of which 12 RCTs and 4 substudies met selection criteria.Data Extraction and Synthesis: Data were abstracted in duplicate according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline. Pooled effect estimates were calculated using random-effects Mantel-Haenszel models. Interaction P values were used to test for subgroup differences.Main Outcomes and Measures: The primary outcome was HF events, defined as HF hospitalization, clinically significant worsening of HF, or unscheduled visits to a clinician for treatment intensification. Secondary outcomes included cardiovascular and all-cause mortality.Results: A total of 12 RCTs with 2465 participants (mean [SD] age, 65.3 [9.7] years; 658 females [26.7%]) were included; there were 1552 participants with HFrEF and 913 participants with HFpEF. Compared with conventional rate or rhythm control, catheter ablation was associated with reduced risk of HF events in HFrEF (risk ratio [RR], 0.59; 95% CI, 0.48-0.72), while there was no benefit in patients with HFpEF (RR, 0.93; 95% CI, 0.65-1.32) (P for interaction = .03). Catheter ablation was associated with reduced risk of cardiovascular death compared with conventional therapies in HFrEF (RR, 0.49; 95% CI, 0.34-0.70) but a differential association was not detected in HFpEF (RR, 0.91; 95% CI, 0.46-1.79) (P for interaction = .12). Similarly, no difference in the association of catheter ablation with all-cause mortality was found between HFrEF (RR vs conventional therapies, 0.63; 95% CI, 0.47-0.86) and HFpEF (RR vs conventional therapies, 0.95; 95% CI, 0.39-2.30) groups (P for interaction = .39).Conclusions and Relevance: This study found that catheter ablation for AF was associated with reduced risk of HF events in patients with HFrEF but had limited or no benefit in HFpEF. Results from ongoing trials may further elucidate the role of catheter ablation for AF in HFpEF.


  • Open Access

    Timing of detection of atrial fibrillation recurrence in patients with transient new-onset atrial fibrillation detected during hospitalization for noncardiac surgery or medical illness

    by W F Mcintyre, L S Johnson, M E Vadakken, N R Latendresse, F Kribo, C Ramasundarahettige, J A Wong, J S Healey

    Background: Approximately one third of patients who experience transient new-onset atrial fibrillation (AF) during a hospitalization for noncardiac surgery or medical illness will have recurrent AF within 1 year. Purpose: To estimate the expected rate of detection of AF recurrence using different durations of continuous ECG monitoring during follow-up of patients who have had AF occurring transiently during physiologic stress. Methods: We used continuous ECG data from participants enrolled in the AFOTS Follow-up Study. Participants had transient new-onset AF while hospitalized for noncardiac surgery or medical illness and were discharged from hospital in sinus rhythm. We calculated the median time to detection of the first recurrent AF episode and the proportion of recurrent AF events that would be captured with an ECG monitor worn for 24 h, 48 h, 7 days and 14 days, and with a repeated 14-day monitor worn approximately 6 months after the first monitor. Results: A total of 139 participants (41.0% female, median CHA2DS2-VaSC Score 3.0 (Interquartile Range [IQR] 2.0- 4.0)) wore at least one ECG monitor for a median of 13.5 days (IQR 11.7-13.8). A second ECG monitor was worn by 83 (59.7%) participants for a median of 12.9 days (IQR 10.0-13.9); the second monitor was worn a median of 175.0 days (IQR 153.0-216.0) after the first monitor. Among the study participants in whom recurrent AF was detected (n = 40, 28.8%), the median time to AF lasting at least 30 seconds was 128.0 hours (IQR 32.5-232.5). The proportion of AF recurrences detected after more than 24 hours of monitoring was 75.0% (n = 30). The yield of AF detection increased with longer monitoring times (Figure 1). AF was detected in 5.0% of participants at 24 hours, 5.8% at 48 hours, 6.5% at 72 hours, 12.2% at 7 days, 21.6% at 14 days and in 28.8% of participants by the end of the second 14-day monitor. Conclusions: In patients who have experienced transient new-onset AF during a hospitalization for noncardiac surgery or medical illness, the rate of capture of AF recurrence in follow-up increases with longer monitoring durations. 14-day monitors capture nearly 4 times as many AF events as 48 h monitors.

  • Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis of clinical trials

    by Alireza Oraii, Jeff S Healey, Krzysztof Kowalik, Avinash K Pandey, Alexander P Benz, Jorge A Wong, David Conen, William F McIntyre

    Mineralocorticoid receptor antagonists (MRAs) improve cardiovascular outcomes in a variety of settings. This study aimed to assess whether cardioprotective effects of MRAs are modified by heart failure (HF) and atrial fibrillation (AF) status and to study their impact on AF events. MEDLINE, Embase, and Cochrane Central databases were searched to 24 March 2023 for randomized controlled trials evaluating the efficacy of MRAs as compared with placebo or usual care in reducing cardiovascular outcomes and AF events in patients with or at risk for cardiovascular diseases. Random-effects models and interaction analyses were used to test for effect modification. Meta-analysis of seven trials (20 741 participants, mean age: 65.6 years, 32% women) showed that the efficacy of MRAs, as compared with placebo, in reducing a composite of cardiovascular death or HF hospitalization remains consistent across patients with HF [risk ratio = 0.81; 95% confidence interval (CI): 0.67–0.98] and without HF (risk ratio = 0.84; 95% CI: 0.75–0.93; interaction P = .77). Among patients with HF, MRAs reduced cardiovascular death or HF hospitalization in patients with AF (hazard ratio = 0.95; 95% CI: 0.54–1.66) to a similar extent as in those without AF (hazard ratio = 0.82; 95% CI: 0.63–1.07; interaction P = .65). Pooled data from 20 trials (21 791 participants, mean age: 65.2 years, 31.3% women) showed that MRAs reduce AF events (risk ratio = 0.76; 95% CI: 0.67–0.87) in both patients with and without prior AF. Mineralocorticoid receptor antagonists are similarly effective in preventing cardiovascular events in patients with and without HF and most likely retain their efficacy regardless of AF status. Mineralocorticoid receptor antagonists may also be moderately effective in preventing incident or recurrent AF events. Mineralocorticoid receptor antagonists and atrial fibrillation. AF, atrial fibrillation; CI, confidence interval; CV, cardiovascular; HF, heart failure; MRA, mineralocorticoid receptor antagonist; RCT, randomized controlled trial.


  • Colchicine to Prevent Atrial Fibrillation Recurrence After Catheter Ablation: A Randomized, Placebo-Controlled Trial

    by Alexander P. Benz, Guy Amit, Stuart J. Connolly, Jasrita Singh, Juan G. Acosta-Vélez, David Conen, Bishoy Deif, Syamkumar Divakaramenon, William F. McIntyre, Viwe Mtwesi, et al.

    BACKGROUND: Inflammation may promote atrial fibrillation (AF) recurrence after catheter ablation. This study aimed to evaluate a short-term anti-inflammatory treatment with colchicine following ablation of AF. METHODS: Patients scheduled for ablation were randomized to receive colchicine 0.6 mg twice daily or placebo for 10 days. The first dose of the study drug was administered within 4 hours before ablation. Atrial arrhythmia recurrence was defined as AF, atrial flutter, or atrial tachycardia >30 s on two 14-day Holters performed immediately and at 3 months following ablation. RESULTS: The modified intention-to-treat population included 199 patients (median age, 61 years; 22% female; 70% first procedure) who underwent radiofrequency (79%) or cryoballoon ablation (21%) of AF. Antiarrhythmic drugs were prescribed at discharge in 149 (75%) patients. Colchicine did not prevent atrial arrhythmia recurrence at 2 weeks (31% versus 32%; hazard ratio [HR], 0.98 [95% CI, 0.59–1.61]; P =0.92) or at 3 months following ablation (14% versus 15%; HR, 0.95 [95% CI, 0.45–2.02]; P =0.89). Postablation chest pain consistent with pericarditis was reduced with colchicine (4% versus 15%; HR, 0.26 [95% CI, 0.09–0.77]; P =0.02) and colchicine increased diarrhea (26% versus 7%; HR, 4.74 [95% CI, 1.95–11.53]; P P =0.55). CONCLUSIONS: Colchicine administered for 10 days following catheter ablation did not reduce atrial arrhythmia recurrence or AF-associated clinical events, but did reduce postablation chest pain and increase diarrhea.


  • Atrial Fibrillation Recurrence in Patients With Transient New-Onset Atrial Fibrillation Detected During Hospitalization for Noncardiac Surgery or Medical Illness

    by William F. McIntyre, Maria E. Vadakken, Stuart J. Connolly, Pablo A. Mendoza, Alexandra P. Lengyel, Anand S. Rai, Nicole R. Latendresse, Alex J. Grinvalds, Chinthanie Ramasundarahettige, J. Gabriel Acosta, et al.

    Atrial fibrillation (AF) is often detected for the first time in patients who are hospitalized for another reason. Long-term risks for AF recurrence in these patients are unclear. To estimate risk for AF recurrence in patients with new-onset AF during a hospitalization for noncardiac surgery or medical illness compared with a matched population without AF. Matched cohort study. (ClinicalTrials.gov: NCT03221777). Three academic hospitals in Hamilton, Ontario, Canada. The study enrolled patients hospitalized for noncardiac surgery or medical illness who had transient new-onset AF. For each participant, an age- and sex-matched control participant with no history of AF from the same hospital ward was recruited. All participants left the hospital in sinus rhythm. 14-day electrocardiographic (ECG) monitor at 1 and 6 months and telephone assessment at 1, 6, and 12 months. The primary outcome was AF lasting at least 30 seconds on the monitor or captured by ECG 12-lead during routine care at 12 months. Among 139 participants with transient new-onset AF (70 patients with medical illness and 69 surgical patients) and 139 matched control participants, the mean age was 71 years (SD, 10), the mean CHA2DS2-VASc score was 3.0 (SD, 1.5), and 59% were male. The median duration of AF during the index hospitalization was 15.8 hours (IQR, 6.4 to 49.6 hours). After 1 year, recurrent AF was detected in 33.1% (95% CI, 25.3% to 40.9%) of participants in the transient new-onset AF group and 5.0% (CI, 1.4% to 8.7%) of matched control participants; after adjustment for the number of ECG monitors worn and for baseline clinical differences, the adjusted relative risk was 6.6 (CI, 3.2 to 13.7). After exclusion of participants who had electrical or pharmacologic cardioversion during the index hospitalization (n = 40) and their matched control participants and limiting to AF events detected by the patch ECG monitor, recurrent AF was detected in 32.3% (CI, 23.1% to 41.5%) of participants with transient new-onset AF and 3.0% (CI, 0% to 6.4%) of matched control participants. Generalizability is limited, and the study was underpowered to evaluate subgroups and clinical predictors. Among patients who have transient new-onset AF during a hospitalization for noncardiac surgery or medical illness, approximately 1 in 3 will have recurrent AF within 1 year. Peer-reviewed grants.